Refractory Cancer
55
20
26
14
Key Insights
Highlights
Success Rate
74% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
5 terminated out of 55 trials
73.7%
-12.8% vs benchmark
2%
1 trials in Phase 3/4
14%
2 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (55)
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
A Study of Avutometinib for People With Solid Tumor Cancers
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Individualized Treatments in Adults With Relapsed/Refractory Cancers
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Plan Development for Giving Teclistamab in the Outpatient Setting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
9-ING-41 in Pediatric Patients With Refractory Malignancies.
A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.